Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 18/20 | 0.74 |
| ▸ | SSTR5 | P35346 | 10/20 | 0.71 |
| ▸ | SSTR4 | P31391 | 10/20 | 0.71 |
| ▸ | SSTR3 | P32745 | 4/20 | 0.68 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17404744 | 0.93 | SSTR2 (0.83) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| SCHEMBL17404625 | 0.93 | SSTR2 (0.83) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| SCHEMBL25500426 | 0.93 | SSTR2 (0.83) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| SCHEMBL21892076 | 0.92 | SSTR2 (0.82) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| SCHEMBL18712544 | 0.92 | SSTR2 (0.82) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| SCHEMBL17404645 | 0.92 | SSTR2 (0.72) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| SCHEMBL13814081 | 0.90 | SSTR2 (0.86) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| SCHEMBL17404484 | 0.89 | SSTR2 (0.81) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| SCHEMBL17404734 | 0.89 | SSTR2 (0.87) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| SCHEMBL21892144 | 0.89 | SSTR2 (0.81) | SSTR2SSTR5SSTR4SSTR3SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090162290-A1 | METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF | THERAPHARM GMBH | 2009-06-25 | — | — | US | disclosed |
| US-20090162290-A1 | METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF | THERAPHARM GMBH | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162290-A1 | METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF | C5, C3AR1, SPR | SSTR2 886/4885SSTR5 63/4885SSTR4 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.